Spain vs Switzerland: Share of the population living with HIV receiving antiretroviral therapy
Spain
90.4%
in 2022
Switzerland
89.8%
in 2023
Spain rank
18th
Switzerland rank
19th
Share of the population living with HIV receiving antiretroviral therapy over time
- Spain
- Switzerland
How they compare
Spain currently reports 90.4% against 89.8% in Switzerland, a difference of 0.6%.
The two have swapped places 3 times across 33 shared years of data; in 1990 it was Switzerland ahead.
Spain ranks 18th and Switzerland ranks 19th of 149 countries.
Switzerland has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Spain | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 5.3% | 6.9% | 1.7% | Switzerland |
| 2000s | 44.3% | 51.0% | 6.8% | Switzerland |
| 2010s | 75.3% | 80.3% | 5.0% | Switzerland |
| 2020s | 88.3% | 90.3% | 2.0% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Spain or Switzerland?
- Spain, at 90.4% against 89.8% in Switzerland as of 2022.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Spain and Switzerland?
- 0.6%, with Spain ahead.
- How many years of comparable data are there for Spain and Switzerland?
- 33 years are reported by both, from 1990 to 2022.
- How do Spain and Switzerland rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Spain ranks 18th and Switzerland ranks 19th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.